Search ZIVO
Zivo Bioscience, Inc.
OTC · CIK 1101026
Last close4.01
Daily change+0.47 (13.28%)
10 Years gain-83.29%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ZIVO · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
66.7Momentum
100.0Acceleration
100.0Confidence
62.0Annual Revenue18
Quarterly Revenue51
Annual CFO18
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality12.5 / 25
Capital Efficiency20.0 / 20
Balance Sheet5.8 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 18959.0093 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 6.4185 percentage points.
Heavy share dilution · HIGHDiluted share count increased 28.8886%.
Low interest coverage · HIGHInterest coverage is -291.5707x.
Key Metrics
Revenue Growth TTM191.88%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Margin32.33%OK
Operating Margin-6,058.82%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-1,054.6%OK
Net Debt / CFO0.02xOK
Diluted Share Growth 1Y28.89%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 FY Dec 31, 2024 | $157,220.00 | $48,952.00 | -$13.36M | -$4.31M | n/a | 31.14% | -8,498.85% | n/a | n/a | 3.17M |
| 2024 FY Dec 31, 2023 | $27,650.00 | $11,610.00 | -$7.26M | -$5.80M | n/a | 41.99% | -26,267.67% | n/a | n/a | 1.69M |
| 2023 FY Dec 31, 2022 | $0.00 | $0.00 | -$8.73M | -$7.10M | n/a | n/a | n/a | n/a | n/a | n/a |
| 2022 FY Dec 31, 2021 | $0.00 | $0.00 | -$8.65M | -$6.80M | n/a | n/a | n/a | n/a | n/a | n/a |
| 2021 FY Dec 31, 2020 | $20,000.00 | $20,000.00 | -$8.56M | -$2.59M | n/a | 100% | -42,778.38% | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $150,525.00 | sum latest 4 fiscal quarters Revenue | OK | 0001654954-25-013095, 0001654954-25-005748 |
| Revenue Growth TTM | 191.88% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001654954-25-013095, 0001654954-25-005748 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-25-002948 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001654954-25-002948 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001654954-25-002948 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001654954-25-013095, 0001654954-25-005748 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 32.33% | Gross Profit / Revenue | OK | 0001654954-25-013095, 0001654954-25-005748 |
| Operating Margin | -6,058.82% | Operating Income / Revenue | OK | 0001654954-25-013095, 0001654954-25-005748 |
| Net Debt / CFO | 0.02x | Net Debt / CFO | OK | 0001654954-25-013095, 0001654954-25-009650 |
| Interest Coverage | -291.57x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 0.08x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.04 | Revenue / Diluted Shares | OK | 0001654954-25-013095, 0001654954-25-005748 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |